Aligos Therapeutics, Inc. (ALGS) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Lawrence Blatt	Chief Executive Officer, President & Chairman of the Board	1.04M	1962
Julian A. Symons DPHIL	Executive Vice President & Chief Scientific Officer	693,977	1962
Lesley Ann Calhoun	Executive Vice President, Chief Financial Officer & Chief Operating Officer	704,760	1966
David Smith	Executive Vice President & Head of Chemical Operations	0	N/A
Kieron Wesson	Vice President & Head of Chemistry Manufacturing Controls	0	N/A
Tse-I Lin	Senior Vice President of Early Compound Development & Belgian Site Head	0	N/A
Nikhil Aneja	Principal Accounting Officer	0	1977
Kristina Engeseth	Senior Vice President and Head of People & Culture	0	N/A
Ramon Polo	Senior VP & Head of Global Regulatory Affairs	0	N/A
Sushmita Chanda DABT	Executive Vice President & Chief Development Officer	0	1967
James Hassard	Executive VP & Chief Commercial Officer	0	1967
Laura Kavanaugh	Vice President & Head of Legal	0	N/A

Name

Title

Pay

Year Born

Lawrence Blatt

Chief Executive Officer, President & Chairman of the Board

1.04M

1962

Julian A. Symons DPHIL

Executive Vice President & Chief Scientific Officer

693,977

1962

Lesley Ann Calhoun

Executive Vice President, Chief Financial Officer & Chief Operating Officer

704,760

1966

David Smith

Executive Vice President & Head of Chemical Operations

N/A

Kieron Wesson

Vice President & Head of Chemistry Manufacturing Controls

N/A

Tse-I Lin

Senior Vice President of Early Compound Development & Belgian Site Head

N/A

Nikhil Aneja

Principal Accounting Officer

1977

Kristina Engeseth

Senior Vice President and Head of People & Culture

N/A

Ramon Polo

Senior VP & Head of Global Regulatory Affairs

N/A

Sushmita Chanda DABT

Executive Vice President & Chief Development Officer

1967

James Hassard

Executive VP & Chief Commercial Officer

1967

Laura Kavanaugh

Vice President & Head of Legal

N/A

Description

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.